Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD11 With Up to 84-day Period of Fixed Daily Dosing, With an Evaluation of Drug-Drug Interactions

NCT07883226 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT07883226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07883226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD11 With Up to 84-day Period of Fixed Daily Dosing, With an Evaluation of Drug-Drug Interactions
Lead sponsor
Gates Medical Research Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 16, 2026
Completion date
May 30, 2027
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants